Search





Search





NewsStocks

Why Emergent BioSciences Stock Plummeted Today

The Motley FoolDec 3, 2024 11:47 PM

View all comments（0）



Emergent BioSolutions (NYSE: EBS) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities. Investors reacted by trading Emergent's stock down by almost 6%, on a day when the S&P 500 (SNPINDEX: ^GSPC) more or less flatlined.

Unloading shares and exercising warrants

The selling parties are mainly entities affiliated with OHA Agency, a business that provided a $250 million term loan to Emergent in August. In return for this, the vaccine maker issued slightly over 1.1 million shares of its common stock to OHA, plus 2.5 million warrants to buy said stock.

In the sale, the sellers will divest up to a bit over 3.6 million Emergent shares. That amount includes the 1.1 million issued shares, plus shares deriving from exercise of the warrants. The company said that the sales would be effected from time to time, and did not provide further details.

Emergent stressed in its filing that it will receive no monies from these sales, as it is not one of the selling parties.

Not a great morale booster

In situations like this, investors are most wary of potential stockholder dilution. That, fortunately for Emergent shareholders, isn't really the case here -- the company has more than 54 million shares outstanding currently. So even in an extreme scenario, the sales won't be worryingly dilutive.

However, any decent-sized divestment risks damaging morale regarding a company's future. After all, even institutional investors are tempted to hang on in situations where a stock could potentially rise to a meaningful degree. It's no wonder the market was discouraged by news of the coming Emergent sales.

Should you invest $1,000 in Emergent BioSolutions right now?

Before you buy stock in Emergent BioSolutions, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Emergent BioSolutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $849,539!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of December 2, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

S&P 500 Index Forecast: Meta, Microsoft, Alphabet and Other Companies Continue Increasing AI Investment, May Support Index Surpassing 8,000 in Second Half of 2026

TradingKey - The S&P 500 index has recently experienced volatility at high levels. As of the U.S. market close on July 16, the S&P 500 index stood at 7,533.77 points, falling 0.51% on the day. Despite the short-term pullback, technical indicators suggest the medium-to-long-term bullish trend remains intact, and institutions continue to hold a positive outlook for the future of the S&P 500.

Apple Hits Record High, Market Cap Surges to $4.9 Trillion: Why Full-Year Gains Lead the Mag 7?

TradingKey - Against the backdrop of a general pullback in the AI sector, Apple (AAPL) has staged an independent rally, driven by its unique ecosystem moat and robust financial performance. After reaching an all-time high of $323.45 on July 13, the share price hit another record high of $327.5 on July 15. Its market capitalization currently stands at $4.81 trillion, making it the second-largest company in the U.S. by market value as it approaches the epic $5 trillion milestone, trailing only Nvidia (NVDA) at $5.13 trillion. In fact, Apple's year-to-date gain in 2026 has reached 16%, also leading the "Mag 7."

SpaceX Negotiates Multi-Billion Dollar Computing Power Deal With Pentagon: Stock Price Drop Does Not Change Wall Street’s Bullish Expectations

Tradingkey - The Wall Street Journal reported that SpaceX (SPCX) is in negotiations with the U.S. Department of Defense to sell computing power. The deal could be valued at billions of dollars, and if finalized, would mark the latest major infrastructure contract for Elon Musk’s integrated rocket, satellite, and artificial intelligence conglomerate. The report noted that the partnership model for this deal is similar to previous agreements SpaceX reached with Alphabet’s Google (GOOGL) and AI firm Anthropic. The negotiations come as the U.S. military seeks to construct data centers within its military bases to bolster its autonomous computing capabilities.

US-Iran Conflict Escalates, International Oil Prices Surge Over 3%: WTI Crude Breaks $81, Strait of Hormuz Shipping Blocked

Tradingkey - On July 17 (ET), as the conflict between the U.S. and Iran continued to escalate, the two major crude oil futures rose again, returning to price levels seen in mid-June. As of press time, WTI crude futures rose over 3% to $81.05, while Brent crude futures also gained more than 3% to $87.01. The confrontation between the two sides has intensified as the fragile ceasefire agreement signed by the U.S. and Iran last month shows further signs of breaking down.

Micron Stock Price Prediction: MU Breaks $898 Support as Memory Boom Faces Capacity Risk

Micron posted record fiscal Q3 revenue of $41.46 billion and guided for $50 billion in Q4 sales, but MU has broken below $897.80 support as investors assess capacity growth and peak memory margins.

Featured Tools